Literature DB >> 3045099

Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms.

R Hoehn-Saric1, D R McLeod, W D Zimmerli.   

Abstract

Some researchers have recently suggested that antidepressants may be superior to benzodiazepines in the alleviation of generalized anxiety. In a 6-week, double-blind, parallel-design study with flexible dosage scheduling, the authors compared the effects of alprazolam with those of imipramine in 60 patients who had generalized anxiety disorder. On rating scales that contained both psychic and somatic symptoms, patients in both treatment groups improved to a similar degree after 2 weeks. However, alprazolam was more effective in attenuating somatic symptoms, and imipramine was more effective in attenuating psychic symptoms such as dysphoria and negative anticipatory thinking. The authors' results suggest that, in generalized anxiety, somatic symptoms and hyperarousal selectively respond to drugs acting on the gamma-aminobutyric acid system, whereas psychic symptoms respond to treatments affecting the noradrenergic or serotonergic systems.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3045099

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  14 in total

1.  Effects of alprazolam and imipramine on parasympathetic cardiac control in patients with generalized anxiety disorder.

Authors:  D R McLeod; R Hoehn-Saric; S W Porges; W D Zimmerli
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review.

Authors:  Jeffrey R Strawn; Laura Geracioti; Neil Rajdev; Kelly Clemenza; Amir Levine
Journal:  Expert Opin Pharmacother       Date:  2018-07       Impact factor: 3.889

3.  Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines.

Authors:  John Huh; Deborah Goebert; Junji Takeshita; Brett Y Lu; Mark Kang
Journal:  Prim Care Companion CNS Disord       Date:  2011

4.  Mixed Anxiety and Depression : Diagnosis and Treatment Options.

Authors:  D Bakish; R Habib; C L Hooper
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

5.  The diagnosis and treatment of generalized anxiety disorder.

Authors:  Borwin Bandelow; Reinhard Boerner J; Siegfried Kasper; Michael Linden; Hans-Ulrich Wittchen; Hans-Jürgen Möller
Journal:  Dtsch Arztebl Int       Date:  2013-04-26       Impact factor: 5.594

Review 6.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

7.  Psychiatric and Somatic Markers of Anxiety: Identification and Pharmacologic Treatment.

Authors:  Alan J. Gelenberg
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-04

Review 8.  The psychopharmacologic treatment of depression and anxiety in the context of chronic pain.

Authors:  Sunil Verma; Rollin M Gallagher
Journal:  Curr Pain Headache Rep       Date:  2002-02

9.  Psychopharmacology of anxiety disorders.

Authors:  Giovanni B Cassano; Nicolò Baldini Rossi; Stefano Pini
Journal:  Dialogues Clin Neurosci       Date:  2002-09       Impact factor: 5.986

10.  A Real-World, Prospective, Multicenter, Single-Arm Observational Study of Duloxetine in Patients With Major Depressive Disorder or Generalized Anxiety Disorder.

Authors:  Gyorgy Szekeres; Sandor Rozsa; Peter Dome; Gabor Barsony; Xenia Gonda
Journal:  Front Psychiatry       Date:  2021-06-17       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.